Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$29.54

0.74 (2.57%)

08:18
02/15/18
02/15
08:18
02/15/18
08:18

FDA PDUFA Date for Exelixis CABOMETYX (cabozantinib) is February 15, 2018

  • 15

    Feb

EXEL Exelixis
$29.54

0.74 (2.57%)

01/04/18
PIPR
01/04/18
NO CHANGE
Target $37
PIPR
Overweight
Piper ups Exelixis target to $37, names a top pick for 2018
Piper Jaffray analyst Edward Tenthoff names Exelixis a top pick for 2018 and raised his price target for the shares to $37 from $33. The analyst expects Cabometyx growth from driven label expansion and is positive into the Phase III Cotexo data in the first half of 2018.
10/17/17
NEED
10/17/17
NO CHANGE
Target $33
NEED
Buy
Exelixis price target raised to $33 from $30 at Needham
Needham analyst Chad Messer raised his price target on Exelixis (EXEL) to $33, noting the latest trial data for advanced renal cell carcinoma treatment, Cabozantinib, positions it for near and long term growth. Messer says the results may be sufficient to allay competitive concerns from the recently approved Bayer (BAYRY) Stivarga, as cabozantinib offers a potentially more attractive efficacy profile.
10/16/17
PIPR
10/16/17
NO CHANGE
Target $33
PIPR
Overweight
Exelixis price target raised to $33 from $29 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Exelixis shares to $33 after the company said the Phase III Celestial trial of Cabometyx met the primary endpoint. The analyst is confident front-line approval next year will grow renal cell carcinoma product sales to $392M in 2018. He reiterates an Overweight rating on Exelixis.
10/16/17
RHCO
10/16/17
NO CHANGE
Target $35
RHCO
Buy
Cabo result better positions Exelixis as acquisition target, says SunTrust
SunTrust analyst Peter Lawson raised his price target on Exelixis (EXEL) to $35 from $33 and maintained his Buy rating, saying the latest CELESTIAL trial cabozantinib positions the treatment well against its main competitor - Bayer's (BAYRY) Regorafenib. Lawson adds that the trial result validates the expansion of cabozantinib beyond kidney cancer and better positions Exelixis as a potentially attractive M&A target.

TODAY'S FREE FLY STORIES

AMRX

Amneal Pharmaceuticals

$16.33

-0.24 (-1.45%)

07:32
12/14/18
12/14
07:32
12/14/18
07:32
Downgrade
Amneal Pharmaceuticals rating change  »

Amneal downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

GE

General Electric

$7.20

0.48 (7.14%)

, OSTK

Overstock.com

$17.97

-1.13 (-5.92%)

07:30
12/14/18
12/14
07:30
12/14/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

GE

General Electric

$7.20

0.48 (7.14%)

OSTK

Overstock.com

$17.97

-1.13 (-5.92%)

GME

GameStop

$12.79

-0.445 (-3.36%)

ESRX

Express Scripts

$98.94

2.03 (2.09%)

CC

Chemours

$27.15

0.485 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:30
12/14/18
12/14
07:30
12/14/18
07:30
General news
Treasury Market Outlook: yields are dropped on risk-off flows »

Treasury Market Outlook:…

SEE

Sealed Air

$32.41

-1.05 (-3.14%)

07:29
12/14/18
12/14
07:29
12/14/18
07:29
Upgrade
Sealed Air rating change  »

Sealed Air upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$247.71

2.27 (0.92%)

07:27
12/14/18
12/14
07:27
12/14/18
07:27
Recommendations
Adobe analyst commentary  »

Adobe valuation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COST

Costco

$226.41

-1.41 (-0.62%)

07:25
12/14/18
12/14
07:25
12/14/18
07:25
Recommendations
Costco analyst commentary  »

Costco price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$137.58

-0.26 (-0.19%)

07:25
12/14/18
12/14
07:25
12/14/18
07:25
Conference/Events
Visa management to meet with Wedbush »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 29

    Jan

BECN

Beacon Roofing

$31.84

-0.22 (-0.69%)

07:24
12/14/18
12/14
07:24
12/14/18
07:24
Downgrade
Beacon Roofing rating change  »

Beacon Roofing downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REG

Regency Centers

$62.26

0.06 (0.10%)

07:24
12/14/18
12/14
07:24
12/14/18
07:24
Downgrade
Regency Centers rating change  »

Regency Centers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

DRGDF

Detour Gold

$0.00

(0.00%)

07:19
12/14/18
12/14
07:19
12/14/18
07:19
Downgrade
Detour Gold rating change  »

Detour Gold downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$186.53

2.99 (1.63%)

, YUM

Yum! Brands

$93.49

3.02 (3.34%)

07:19
12/14/18
12/14
07:19
12/14/18
07:19
Recommendations
McDonald's, Yum! Brands analyst commentary  »

JPMorgan calls…

MCD

McDonald's

$186.53

2.99 (1.63%)

YUM

Yum! Brands

$93.49

3.02 (3.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NNN

National Retail Properties

$50.86

0.94 (1.88%)

07:18
12/14/18
12/14
07:18
12/14/18
07:18
Downgrade
National Retail Properties rating change  »

National Retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRGDF

Detour Gold

$0.00

(0.00%)

07:16
12/14/18
12/14
07:16
12/14/18
07:16
Downgrade
Detour Gold rating change  »

Detour Gold downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLCM

Bellicum Pharmaceuticals

$3.60

-0.155 (-4.13%)

07:15
12/14/18
12/14
07:15
12/14/18
07:15
Hot Stocks
Bellicum Pharmaceuticals reports data from BPX-601 at ESMO-IO »

Bellicum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THG

Hanover Insurance

$109.52

-0.68 (-0.62%)

07:14
12/14/18
12/14
07:14
12/14/18
07:14
Conference/Events
Hanover Insurance management to meet with Buckingham »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 19

    Dec

BHC

Bausch Health

$23.65

-0.47 (-1.95%)

07:12
12/14/18
12/14
07:12
12/14/18
07:12
Upgrade
Bausch Health rating change  »

Bausch Health upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 25

    Feb

IDRA

Idera Pharmaceuticals

$6.60

-0.06 (-0.90%)

07:10
12/14/18
12/14
07:10
12/14/18
07:10
Hot Stocks
Idera Pharmaceuticals presents data from Phase 2 expansion of ILUMMINATE-204 »

Idera Pharmaceuticals has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

RBA

Ritchie Bros.

$32.39

-0.28 (-0.86%)

07:08
12/14/18
12/14
07:08
12/14/18
07:08
Hot Stocks
Ritchie Bros. sells C$639M+ of equipment in Edmonton auction »

Ritchie Bros. held its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$66.90

0.8 (1.21%)

07:07
12/14/18
12/14
07:07
12/14/18
07:07
Recommendations
Starbucks analyst commentary  »

Starbucks story regaining…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

VLKAY

Volkswagen

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

07:07
12/14/18
12/14
07:07
12/14/18
07:07
Hot Stocks
EU passenger car registrations down 8.0% in November »

In November, passenger…

VLKAY

Volkswagen

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$120.89

-1.04 (-0.85%)

F

Ford

$8.50

-0.135 (-1.56%)

HMC

Honda

$27.23

-0.03 (-0.11%)

GM

General Motors

$35.11

-0.58 (-1.63%)

FCAU

Fiat Chrysler

$15.67

-0.18 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

CPRX

Catalyst Pharmaceuticals

$2.47

0.075 (3.14%)

07:06
12/14/18
12/14
07:06
12/14/18
07:06
Recommendations
Catalyst Pharmaceuticals analyst commentary  »

Catalyst Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REXR

Rexford Industrial

$31.42

0.09 (0.29%)

07:06
12/14/18
12/14
07:06
12/14/18
07:06
Hot Stocks
Rexford Industrial acquires industrial property for $18.2M »

Rexford Industrial Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COST

Costco

$226.41

-1.41 (-0.62%)

07:05
12/14/18
12/14
07:05
12/14/18
07:05
Recommendations
Costco analyst commentary  »

Costco price target cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:05
12/14/18
12/14
07:05
12/14/18
07:05
General news
Futures lower after underwhelming Chinese data »

Stock futures are…

LPTX

Leap Therapeutics

$2.85

-0.27 (-8.65%)

07:04
12/14/18
12/14
07:04
12/14/18
07:04
Hot Stocks
Leap Therapeutics presents final data from the Phase I/II study of DKN-01 »

Leap provided the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.